Literature DB >> 9920403

Thiol-disulfide redox buffers maintain a structure of immunoglobulin A that is essential for optimal in vitro binding to secretory component.

R M Jones1, F Schweikart, S Frutiger, J C Jaton, G J Hughes.   

Abstract

We have shown that human secretory component (SC) binds in vitro to different samples of human and murine dimeric immunoglobulin A (IgA). The binding ratio in the IgA/SC complex is 1:1. IgA which is stably bound to SC is separated from unreacted IgA by anion exchange chromatography. A part of IgA/SC complexes formed in vitro is unstable to this elution; the proportion varies between different samples of IgA; it increases following prolonged incubation of IgA at 37 degrees C. Incubation of IgA with glutathione/glutathione disulfide (GSH/GSSG) redox buffers increases the proportion able to form a stable complex with SC to approximately 90%. The presence of bound SC is not essential for this process but does allow it to occur at a lower GSH/GSSG concentration. The stable IgA/SC complex consists of a structure with a disulfide bond between IgA and SC apparently in equilibrium with a structure in which this bond is absent. The proportion bound covalently is similar for different samples of IgA and is insensitive to incubation with GSH/GSSG. It is significantly greater for secretory IgA (sIgA) and for IgA and SC incubated together with a starting mixture of cysteine/cystine. Monoclonal, antigen-specific IgA, all of which is optimally bound to SC in essentially the same way as in native sIgA, can be isolated in high yield. Our results support a mechanism for optimal binding of IgA to SC, that can occur both in vitro and in vivo, in which a thiol disulfide interchange occurs between a free IgA thiol and a sensitive SC disulfide following the initial non-covalent interaction.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9920403     DOI: 10.1016/s0167-4838(98)00239-8

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  6 in total

Review 1.  Recombinant IgA production for mucosal passive immunization, advancing beyond the hurdles.

Authors:  Vikram Virdi; Paloma Juarez; Veronique Boudolf; Ann Depicker
Journal:  Cell Mol Life Sci       Date:  2015-10-28       Impact factor: 9.261

2.  Recombinant immunoglobulin A specific for influenza A virus hemagglutinin: production, functional analysis, and formation of secretory immunoglobulin A.

Authors:  Kentaro Shoji; Tadanobu Takahashi; Kohta Kurohane; Koki Iwata; Takeshi Matsuoka; Shogo Tsuruta; Takatomo Sugino; Masaki Miyake; Takashi Suzuki; Yasuyuki Imai
Journal:  Viral Immunol       Date:  2015-02-06       Impact factor: 2.257

3.  Structural basis for evasion of IgA immunity by Staphylococcus aureus revealed in the complex of SSL7 with Fc of human IgA1.

Authors:  Paul A Ramsland; Natasha Willoughby; Halina M Trist; William Farrugia; P Mark Hogarth; John D Fraser; Bruce D Wines
Journal:  Proc Natl Acad Sci U S A       Date:  2007-09-11       Impact factor: 11.205

4.  IgA as a potential candidate for enteric monoclonal antibody therapeutics with improved gastrointestinal stability.

Authors:  Aaron L Wallace; Matthew I Schneider; Jacqueline R Toomey; Ryan M Schneider; Mark S Klempner; Yang Wang; Lisa A Cavacini
Journal:  Vaccine       Date:  2020-10-08       Impact factor: 3.641

5.  Plant-derived secretory component forms secretory IgA with shiga toxin 1-specific dimeric IgA produced by mouse cells and whole plants.

Authors:  Katsuhiro Nakanishi; Shota Morikane; Nao Hosokawa; Yuka Kajihara; Kohta Kurohane; Yasuo Niwa; Hirokazu Kobayashi; Yasuyuki Imai
Journal:  Plant Cell Rep       Date:  2018-11-30       Impact factor: 4.570

6.  Acinetobacter baumannii Gastrointestinal Colonization Is Facilitated by Secretory IgA Which Is Reductively Dissociated by Bacterial Thioredoxin A.

Authors:  Patrick M Ketter; Jieh-Juen Yu; M Neal Guentzel; Holly C May; Rishein Gupta; Mark Eppinger; Karl E Klose; J Seshu; James P Chambers; Andrew P Cap; Bernard P Arulanandam
Journal:  MBio       Date:  2018-07-10       Impact factor: 7.867

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.